# ImmuneBridge

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunebridge

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.immunebridge.com
- Total disclosed funding: $22M
- Latest round: Seed (Apr 12, 2023)
- Investors on record: 5

## About

Based in California, US, and founded in 2018 by CEO Peretz Partensky and Jesse Cotari, ImmuneBridge Inc., a.k.a. ImmuneBridge operates as a biotech company that develops allogeneic cellular immunotherapies for hematologic malignancies and solid tumors. In April 2023, ImmuneBridge Inc. raised USD 12 million in seed funding co-led by Insight Partners, Merck Ventures, Gaingels Syndicate, and One Way Ventures.

The company offers a cellular discovery platform that uses cord blood for the purpose of screening and selecting cancer-fighting cells. ImmuneBridge develops allogeneic, off-the-shelf cellular immunotherapies, starting with natural killer (NK) cell-based immunotherapies, which originate from CD34+ hematopoietic stem cells (HSCs).

ImmuneBridge plans to use the proceeds from April 2023 funding to build a screening dataset for indication-optimized NK cells, demonstrate scalable manufacturability, and generate pre-clinical data for a lead product.

## Funding rounds

- Seed, Apr 12, 2023, $12M — Insight Partners, M Ventures, Gaingels, One Way Ventures
- Seed, Dec 27, 2022, $10M — Insight Partners, M Ventures, Gaingels, One Way Ventures
- Seed, Jul 21, 2022 — Pioneer Fund

## Investors

- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed
- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Seed
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Seed
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Seed
- One Way Ventures (https://capitalatlas.ai/funds/one-way-ventures) — Seed